Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study
Identifieur interne : 001596 ( Istex/Corpus ); précédent : 001595; suivant : 001597Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study
Auteurs : F. Chen ; X. Lu ; X. Shu ; Q. Peng ; X. Tian ; G. WangSource :
- Internal Medicine Journal [ 1444-0903 ] ; 2015-06.
Abstract
Background: Interstitial lung disease (ILD) is one of the most common and devastated complication of polymyositis/dermatomyositis (PM/DM). Several studies have focused on serum biomarkers for ILD in PM/DM patients; however, there have been no prospective studies. Aim: To explore and compare the predictive value of four serum markers for the development of ILD in patients with PM/DM. Methods: One hundred adult PM/DM patients were included in this prospective clinical study at baseline. Forty‐four PM/DM patients without ILD were followed up for 1 year. Fifty‐six PM/DM patients with ILD were treated and followed up for 2 months. Serum samples were analysed for the levels of Krebs von den Lungen‐6 (KL‐6), monocyte chemotactic protein‐1 (MCP‐1), surfactant protein‐A and D (SP‐A, SP‐D). Results: Serum KL‐6 (1542.8 ± 760.8 U/mL) (P < 0.001), MCP‐1 (1870 ± 1590 pg/mL) (P = 0.014), SP‐A (56 ± 28 ng/mL) (P < 0.001) and SP‐D (230 ± 196 ng/mL) (P < 0.001) were significantly elevated in PM/DM patients with ILD compared with those in the patients without ILD (KL‐6 429 ± 105.8 U/mL; MCP‐1 1349 ± 1303 pg/mL; SP‐A 34 ± 26 ng/mL; SP‐D 96 ± 63 ng/mL). In PM/DM patients without ILD who were followed up for 1 year, KL‐6 presented the highest predictive value among single markers. In patients who were treated and followed up, KL‐6 concentrations increased with the progression of ILD and decreased along with the improvement of ILD. Conclusion: Considering the ability of KL‐6 for predicting the onset of ILD and monitoring the treatment response of ILD in PM/DM patients, it may be of great significance for clinical practice, and the prognosis of patients may be substantially improved if serum KL‐6 was regularly monitored.
Url:
DOI: 10.1111/imj.12754
Links to Exploration step
ISTEX:249174A4FE3F03904034F8D234EFBBD08C7B3A72Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study</title><author><name sortKey="Chen, F" sort="Chen, F" uniqKey="Chen F" first="F." last="Chen">F. Chen</name><affiliation><mods:affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Lu, X" sort="Lu, X" uniqKey="Lu X" first="X." last="Lu">X. Lu</name><affiliation><mods:affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Shu, X" sort="Shu, X" uniqKey="Shu X" first="X." last="Shu">X. Shu</name><affiliation><mods:affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Peng, Q" sort="Peng, Q" uniqKey="Peng Q" first="Q." last="Peng">Q. Peng</name><affiliation><mods:affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Tian, X" sort="Tian, X" uniqKey="Tian X" first="X." last="Tian">X. Tian</name><affiliation><mods:affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Wang, G" sort="Wang, G" uniqKey="Wang G" first="G." last="Wang">G. Wang</name><affiliation><mods:affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</mods:affiliation></affiliation><affiliation><mods:affiliation>Guochun Wang, Department of Rheumatology, China‐Japan Friendship Hospital, Yinghua East Road, Chaoyang District, 100029 Beijing, China.Email:</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: guochunwang@hotmail.com</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:249174A4FE3F03904034F8D234EFBBD08C7B3A72</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1111/imj.12754</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-ZKV2GC5X-V/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001596</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001596</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study</title><author><name sortKey="Chen, F" sort="Chen, F" uniqKey="Chen F" first="F." last="Chen">F. Chen</name><affiliation><mods:affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Lu, X" sort="Lu, X" uniqKey="Lu X" first="X." last="Lu">X. Lu</name><affiliation><mods:affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Shu, X" sort="Shu, X" uniqKey="Shu X" first="X." last="Shu">X. Shu</name><affiliation><mods:affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Peng, Q" sort="Peng, Q" uniqKey="Peng Q" first="Q." last="Peng">Q. Peng</name><affiliation><mods:affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Tian, X" sort="Tian, X" uniqKey="Tian X" first="X." last="Tian">X. Tian</name><affiliation><mods:affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</mods:affiliation></affiliation></author><author><name sortKey="Wang, G" sort="Wang, G" uniqKey="Wang G" first="G." last="Wang">G. Wang</name><affiliation><mods:affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</mods:affiliation></affiliation><affiliation><mods:affiliation>Guochun Wang, Department of Rheumatology, China‐Japan Friendship Hospital, Yinghua East Road, Chaoyang District, 100029 Beijing, China.Email:</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: guochunwang@hotmail.com</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Internal Medicine Journal</title><title level="j" type="alt">INTERNAL MEDICINE JOURNAL</title><idno type="ISSN">1444-0903</idno><idno type="eISSN">1445-5994</idno><imprint><biblScope unit="vol">45</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="641">641</biblScope><biblScope unit="page" to="647">647</biblScope><biblScope unit="page-count">7</biblScope><date type="published" when="2015-06">2015-06</date></imprint><idno type="ISSN">1444-0903</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1444-0903</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Background: Interstitial lung disease (ILD) is one of the most common and devastated complication of polymyositis/dermatomyositis (PM/DM). Several studies have focused on serum biomarkers for ILD in PM/DM patients; however, there have been no prospective studies. Aim: To explore and compare the predictive value of four serum markers for the development of ILD in patients with PM/DM. Methods: One hundred adult PM/DM patients were included in this prospective clinical study at baseline. Forty‐four PM/DM patients without ILD were followed up for 1 year. Fifty‐six PM/DM patients with ILD were treated and followed up for 2 months. Serum samples were analysed for the levels of Krebs von den Lungen‐6 (KL‐6), monocyte chemotactic protein‐1 (MCP‐1), surfactant protein‐A and D (SP‐A, SP‐D). Results: Serum KL‐6 (1542.8 ± 760.8 U/mL) (P < 0.001), MCP‐1 (1870 ± 1590 pg/mL) (P = 0.014), SP‐A (56 ± 28 ng/mL) (P < 0.001) and SP‐D (230 ± 196 ng/mL) (P < 0.001) were significantly elevated in PM/DM patients with ILD compared with those in the patients without ILD (KL‐6 429 ± 105.8 U/mL; MCP‐1 1349 ± 1303 pg/mL; SP‐A 34 ± 26 ng/mL; SP‐D 96 ± 63 ng/mL). In PM/DM patients without ILD who were followed up for 1 year, KL‐6 presented the highest predictive value among single markers. In patients who were treated and followed up, KL‐6 concentrations increased with the progression of ILD and decreased along with the improvement of ILD. Conclusion: Considering the ability of KL‐6 for predicting the onset of ILD and monitoring the treatment response of ILD in PM/DM patients, it may be of great significance for clinical practice, and the prognosis of patients may be substantially improved if serum KL‐6 was regularly monitored.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>F. Chen</name><affiliations><json:string>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</json:string></affiliations></json:item><json:item><name>X. Lu</name><affiliations><json:string>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</json:string></affiliations></json:item><json:item><name>X. Shu</name><affiliations><json:string>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</json:string></affiliations></json:item><json:item><name>Q. Peng</name><affiliations><json:string>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</json:string></affiliations></json:item><json:item><name>X. Tian</name><affiliations><json:string>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</json:string></affiliations></json:item><json:item><name>G. Wang</name><affiliations><json:string>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</json:string><json:string>Guochun Wang, Department of Rheumatology, China‐Japan Friendship Hospital, Yinghua East Road, Chaoyang District, 100029 Beijing, China.Email:</json:string><json:string>E-mail: guochunwang@hotmail.com</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>myositis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>lung disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>interstitial</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>predictive value</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>KL‐6</value></json:item></subject><articleId><json:string>IMJ12754</json:string></articleId><arkIstex>ark:/67375/WNG-ZKV2GC5X-V</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Background: Interstitial lung disease (ILD) is one of the most common and devastated complication of polymyositis/dermatomyositis (PM/DM). Several studies have focused on serum biomarkers for ILD in PM/DM patients; however, there have been no prospective studies. Aim: To explore and compare the predictive value of four serum markers for the development of ILD in patients with PM/DM. Methods: One hundred adult PM/DM patients were included in this prospective clinical study at baseline. Forty‐four PM/DM patients without ILD were followed up for 1 year. Fifty‐six PM/DM patients with ILD were treated and followed up for 2 months. Serum samples were analysed for the levels of Krebs von den Lungen‐6 (KL‐6), monocyte chemotactic protein‐1 (MCP‐1), surfactant protein‐A and D (SP‐A, SP‐D). Results: Serum KL‐6 (1542.8 ± 760.8 U/mL) (P > 0.001), MCP‐1 (1870 ± 1590 pg/mL) (P = 0.014), SP‐A (56 ± 28 ng/mL) (P > 0.001) and SP‐D (230 ± 196 ng/mL) (P > 0.001) were significantly elevated in PM/DM patients with ILD compared with those in the patients without ILD (KL‐6 429 ± 105.8 U/mL; MCP‐1 1349 ± 1303 pg/mL; SP‐A 34 ± 26 ng/mL; SP‐D 96 ± 63 ng/mL). In PM/DM patients without ILD who were followed up for 1 year, KL‐6 presented the highest predictive value among single markers. In patients who were treated and followed up, KL‐6 concentrations increased with the progression of ILD and decreased along with the improvement of ILD. Conclusion: Considering the ability of KL‐6 for predicting the onset of ILD and monitoring the treatment response of ILD in PM/DM patients, it may be of great significance for clinical practice, and the prognosis of patients may be substantially improved if serum KL‐6 was regularly monitored.</abstract><qualityIndicators><score>8.675</score><pdfWordCount>3675</pdfWordCount><pdfCharCount>23092</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>7</pdfPageCount><pdfPageSize>595.276 x 779.528 pts</pdfPageSize><pdfWordsPerPage>525</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>273</abstractWordCount><abstractCharCount>1726</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study</title><genre><json:string>article</json:string></genre><host><title>Internal Medicine Journal</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1445-5994</json:string></doi><issn><json:string>1444-0903</json:string></issn><eissn><json:string>1445-5994</json:string></eissn><publisherId><json:string>IMJ</json:string></publisherId><volume>45</volume><issue>6</issue><pages><first>641</first><last>647</last><total>7</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Original Articles</value></json:item><json:item><value>Original Article</value></json:item></subject></host><ark><json:string>ark:/67375/WNG-ZKV2GC5X-V</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - medicine, general & internal</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - general & internal medicine</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Internal Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2015</publicationDate><copyrightDate>2015</copyrightDate><doi><json:string>10.1111/imj.12754</json:string></doi><id>249174A4FE3F03904034F8D234EFBBD08C7B3A72</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-ZKV2GC5X-V/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-ZKV2GC5X-V/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-ZKV2GC5X-V/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study</title><title level="a" type="short">Predictive value of serum markers</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher ref="https://scientific-publisher.data.istex.fr/ark:/67375/H02-QW5Q88H5-V">Wiley Publishing Ltd</publisher><availability><licence>© 2015 Royal Australasian College of Physicians</licence></availability><date type="published" when="2015-06"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study</title><title level="a" type="short">Predictive value of serum markers</title><author xml:id="author-0000"><persName><forename type="first">F.</forename><surname>Chen</surname></persName><affiliation><orgName type="division">Department of Rheumatology</orgName><orgName type="institution">China‐Japan Friendship Hospital</orgName><address><settlement>Beijing</settlement><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">X.</forename><surname>Lu</surname></persName><affiliation><orgName type="division">Department of Rheumatology</orgName><orgName type="institution">China‐Japan Friendship Hospital</orgName><address><settlement>Beijing</settlement><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">X.</forename><surname>Shu</surname></persName><affiliation><orgName type="division">Department of Rheumatology</orgName><orgName type="institution">China‐Japan Friendship Hospital</orgName><address><settlement>Beijing</settlement><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Q.</forename><surname>Peng</surname></persName><affiliation><orgName type="division">Department of Rheumatology</orgName><orgName type="institution">China‐Japan Friendship Hospital</orgName><address><settlement>Beijing</settlement><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">X.</forename><surname>Tian</surname></persName><affiliation><orgName type="division">Department of Rheumatology</orgName><orgName type="institution">China‐Japan Friendship Hospital</orgName><address><settlement>Beijing</settlement><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><author xml:id="author-0005" role="corresp"><persName><forename type="first">G.</forename><surname>Wang</surname></persName><affiliation><orgName type="division">Department of Rheumatology</orgName><orgName type="institution">China‐Japan Friendship Hospital</orgName><address><settlement>Beijing</settlement><country key="CN" xml:lang="en">CHINA</country></address></affiliation></author><idno type="istex">249174A4FE3F03904034F8D234EFBBD08C7B3A72</idno><idno type="ark">ark:/67375/WNG-ZKV2GC5X-V</idno><idno type="DOI">10.1111/imj.12754</idno><idno type="unit">IMJ12754</idno><idno type="toTypesetVersion">file:IMJ.IMJ12754.pdf</idno></analytic><monogr><title level="j" type="main">Internal Medicine Journal</title><title level="j" type="alt">INTERNAL MEDICINE JOURNAL</title><idno type="pISSN">1444-0903</idno><idno type="eISSN">1445-5994</idno><idno type="book-DOI">10.1111/(ISSN)1445-5994</idno><idno type="book-part-DOI">10.1111/imj.2015.45.issue-6</idno><idno type="product">IMJ</idno><imprint><biblScope unit="vol">45</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="641">641</biblScope><biblScope unit="page" to="647">647</biblScope><biblScope unit="page-count">7</biblScope><date type="published" when="2015-06"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract style="main"><head>Abstract</head><head>Background</head><p>Interstitial lung disease (<hi rend="fc">ILD</hi>) is one of the most common and devastated complication of polymyositis/dermatomyositis (<hi rend="fc">PM</hi>/<hi rend="fc">DM</hi>). Several studies have focused on serum biomarkers for <hi rend="fc">ILD</hi> in <hi rend="fc">PM</hi>/<hi rend="fc">DM</hi> patients; however, there have been no prospective studies.</p><head>Aim</head><p>To explore and compare the predictive value of four serum markers for the development of <hi rend="fc">ILD</hi> in patients with <hi rend="fc">PM</hi>/<hi rend="fc">DM</hi>.</p><head>Methods</head><p>One hundred adult <hi rend="fc">PM</hi>/<hi rend="fc">DM</hi> patients were included in this prospective clinical study at baseline. Forty‐four <hi rend="fc">PM</hi>/<hi rend="fc">DM</hi> patients without <hi rend="fc">ILD</hi> were followed up for 1 year. Fifty‐six <hi rend="fc">PM</hi>/<hi rend="fc">DM</hi> patients with <hi rend="fc">ILD</hi> were treated and followed up for 2 months. Serum samples were analysed for the levels of Krebs von den Lungen‐6 (<hi rend="fc">KL</hi>‐6), monocyte chemotactic protein‐1 (<hi rend="fc">MCP</hi>‐1), surfactant protein‐<hi rend="fc">A</hi> and <hi rend="fc">D</hi> (<hi rend="fc">SP</hi>‐<hi rend="fc">A</hi>, <hi rend="fc">SP</hi>‐<hi rend="fc">D</hi>).</p><head>Results</head><p>Serum <hi rend="fc">KL</hi>‐6 (1542.8 ± 760.8 U/mL) (<hi rend="italic">P</hi> < 0.001), <hi rend="fc">MCP</hi>‐1 (1870 ± 1590 pg/mL) (<hi rend="italic">P</hi> = 0.014), <hi rend="fc">SP</hi>‐A (56 ± 28 ng/mL) (<hi rend="italic">P</hi> < 0.001) and <hi rend="fc">SP</hi>‐<hi rend="fc">D</hi> (230 ± 196 ng/mL) (<hi rend="italic">P</hi> < 0.001) were significantly elevated in <hi rend="fc">PM</hi>/<hi rend="fc">DM</hi> patients with <hi rend="fc">ILD</hi> compared with those in the patients without <hi rend="fc">ILD</hi> (<hi rend="fc">KL</hi>‐6 429 ± 105.8 U/mL; <hi rend="fc">MCP</hi>‐1 1349 ± 1303 pg/mL; <hi rend="fc">SP</hi>‐<hi rend="fc">A</hi> 34 ± 26 ng/mL; <hi rend="fc">SP</hi>‐<hi rend="fc">D</hi> 96 ± 63 ng/mL). In <hi rend="fc">PM</hi>/<hi rend="fc">DM</hi> patients without <hi rend="fc">ILD</hi> who were followed up for 1 year, <hi rend="fc">KL</hi>‐6 presented the highest predictive value among single markers. In patients who were treated and followed up, <hi rend="fc">KL</hi>‐6 concentrations increased with the progression of <hi rend="fc">ILD</hi> and decreased along with the improvement of <hi rend="fc">ILD</hi>.</p><head>Conclusion</head><p>Considering the ability of <hi rend="fc">KL</hi>‐6 for predicting the onset of <hi rend="fc">ILD</hi> and monitoring the treatment response of <hi rend="fc">ILD</hi> in <hi rend="fc">PM</hi>/<hi rend="fc">DM</hi> patients, it may be of great significance for clinical practice, and the prognosis of patients may be substantially improved if serum <hi rend="fc">KL</hi>‐6 was regularly monitored.</p></abstract><textClass><keywords><term xml:id="imj12754-kwd-0001">myositis</term><term xml:id="imj12754-kwd-0002">lung disease</term><term xml:id="imj12754-kwd-0003">interstitial</term><term xml:id="imj12754-kwd-0004">predictive value</term><term xml:id="imj12754-kwd-0005"><hi rend="fc">KL</hi>‐6</term></keywords><keywords rend="tocHeading1"><term>Original Articles</term></keywords><keywords rend="articleCategory"><term>Original Article</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-ZKV2GC5X-V/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body" wicri:toSee="Element #text"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component type="serialArticle" version="2.0" xml:id="imj12754" xml:lang="en"><header><publicationMeta level="product"><doi origin="wiley">10.1111/(ISSN)1445-5994</doi><issn type="print">1444-0903</issn><issn type="electronic">1445-5994</issn><idGroup><id type="product" value="IMJ"></id></idGroup><titleGroup><title sort="INTERNAL MEDICINE JOURNAL" type="main">Internal Medicine Journal</title><title type="short">Intern Med J</title></titleGroup></publicationMeta><publicationMeta level="part" position="60"><doi>10.1111/imj.2015.45.issue-6</doi><copyright ownership="thirdParty">© 2015 Royal Australasian College of Physicians</copyright><numberingGroup><numbering number="45" type="journalVolume">45</numbering><numbering type="journalIssue">6</numbering></numberingGroup><coverDate startDate="2015-06">June 2015</coverDate></publicationMeta><publicationMeta level="unit" position="80" status="forIssue" type="article"><doi>10.1111/imj.12754</doi><idGroup><id type="unit" value="IMJ12754"></id></idGroup><countGroup><count number="7" type="pageTotal"></count></countGroup><titleGroup><title type="tocHeading1">Original Articles</title><title type="articleCategory">Original Article</title></titleGroup><copyright ownership="thirdParty">© 2015 Royal Australasian College of Physicians</copyright><eventGroup><event agent="bestset" date="2015-04-13" type="xmlCreated"></event><event date="2014-10-20" type="manuscriptReceived"></event><event date="2015-03-22" type="manuscriptAccepted"></event><event type="publishedOnlineAccepted" date="2015-03-31"></event><event type="firstOnline" date="2015-06-08"></event><event type="publishedOnlineFinalForm" date="2015-06-08"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.7.2 mode:FullText" date="2016-01-05"></event></eventGroup><numberingGroup><numbering type="pageFirst">641</numbering><numbering type="pageLast">647</numbering></numberingGroup><correspondenceTo><lineatedText><line><b>Correspondence</b></line><line>Guochun Wang, Department of Rheumatology, China‐Japan Friendship Hospital, Yinghua East Road, Chaoyang District, 100029 Beijing, China.</line><line>Email: <email>guochunwang@hotmail.com</email></line></lineatedText></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:IMJ.IMJ12754.pdf"></link></linkGroup></publicationMeta><contentMeta><titleGroup><title type="short">Predictive value of serum markers</title><title type="shortAuthors">Chen <i>et al</i>.</title><title type="main">Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study</title></titleGroup><creators><creator affiliationRef="#imj12754-aff-0001" creatorRole="author" xml:id="imj12754-cr-0001"><personName><givenNames>F.</givenNames><familyName>Chen</familyName></personName></creator><creator affiliationRef="#imj12754-aff-0001" creatorRole="author" xml:id="imj12754-cr-0002"><personName><givenNames>X.</givenNames><familyName>Lu</familyName></personName></creator><creator affiliationRef="#imj12754-aff-0001" creatorRole="author" xml:id="imj12754-cr-0003"><personName><givenNames>X.</givenNames><familyName>Shu</familyName></personName></creator><creator affiliationRef="#imj12754-aff-0001" creatorRole="author" xml:id="imj12754-cr-0004"><personName><givenNames>Q.</givenNames><familyName>Peng</familyName></personName></creator><creator affiliationRef="#imj12754-aff-0001" creatorRole="author" xml:id="imj12754-cr-0005"><personName><givenNames>X.</givenNames><familyName>Tian</familyName></personName></creator><creator affiliationRef="#imj12754-aff-0001" corresponding="yes" creatorRole="author" xml:id="imj12754-cr-0006"><personName><givenNames>G.</givenNames><familyName>Wang</familyName></personName></creator></creators><affiliationGroup><affiliation countryCode="CN" xml:id="imj12754-aff-0001"><orgDiv>Department of Rheumatology</orgDiv><orgName>China‐Japan Friendship Hospital</orgName><address><city>Beijing</city><country>China</country></address></affiliation></affiliationGroup><keywordGroup type="author"><keyword xml:id="imj12754-kwd-0001">myositis</keyword><keyword xml:id="imj12754-kwd-0002">lung disease</keyword><keyword xml:id="imj12754-kwd-0003">interstitial</keyword><keyword xml:id="imj12754-kwd-0004">predictive value</keyword><keyword xml:id="imj12754-kwd-0005"><fc>KL</fc>‐6</keyword></keywordGroup><fundingInfo><fundingAgency>National Natural Science Foundation of China</fundingAgency><fundingNumber>81072457</fundingNumber></fundingInfo><fundingInfo><fundingAgency>Beijing Municipal Science and Technology Commission</fundingAgency><fundingNumber>D101100050010018</fundingNumber></fundingInfo><abstractGroup><abstract type="main"><title type="main">Abstract</title><section xml:id="imj12754-sec-0001"><title type="main">Background</title><p>Interstitial lung disease (<fc>ILD</fc>) is one of the most common and devastated complication of polymyositis/dermatomyositis (<fc>PM</fc>/<fc>DM</fc>). Several studies have focused on serum biomarkers for <fc>ILD</fc> in <fc>PM</fc>/<fc>DM</fc> patients; however, there have been no prospective studies.</p></section><section xml:id="imj12754-sec-0002"><title type="main">Aim</title><p>To explore and compare the predictive value of four serum markers for the development of <fc>ILD</fc> in patients with <fc>PM</fc>/<fc>DM</fc>.</p></section><section xml:id="imj12754-sec-0003"><title type="main">Methods</title><p>One hundred adult <fc>PM</fc>/<fc>DM</fc> patients were included in this prospective clinical study at baseline. Forty‐four <fc>PM</fc>/<fc>DM</fc> patients without <fc>ILD</fc> were followed up for 1 year. Fifty‐six <fc>PM</fc>/<fc>DM</fc> patients with <fc>ILD</fc> were treated and followed up for 2 months. Serum samples were analysed for the levels of Krebs von den Lungen‐6 (<fc>KL</fc>‐6), monocyte chemotactic protein‐1 (<fc>MCP</fc>‐1), surfactant protein‐<fc>A</fc> and <fc>D</fc> (<fc>SP</fc>‐<fc>A</fc>, <fc>SP</fc>‐<fc>D</fc>).</p></section><section xml:id="imj12754-sec-0004"><title type="main">Results</title><p>Serum <fc>KL</fc>‐6 (1542.8 ± 760.8 U/mL) (<i>P</i> < 0.001), <fc>MCP</fc>‐1 (1870 ± 1590 pg/mL) (<i>P</i> = 0.014), <fc>SP</fc>‐A (56 ± 28 ng/mL) (<i>P</i> < 0.001) and <fc>SP</fc>‐<fc>D</fc> (230 ± 196 ng/mL) (<i>P</i> < 0.001) were significantly elevated in <fc>PM</fc>/<fc>DM</fc> patients with <fc>ILD</fc> compared with those in the patients without <fc>ILD</fc> (<fc>KL</fc>‐6 429 ± 105.8 U/mL; <fc>MCP</fc>‐1 1349 ± 1303 pg/mL; <fc>SP</fc>‐<fc>A</fc> 34 ± 26 ng/mL; <fc>SP</fc>‐<fc>D</fc> 96 ± 63 ng/mL). In <fc>PM</fc>/<fc>DM</fc> patients without <fc>ILD</fc> who were followed up for 1 year, <fc>KL</fc>‐6 presented the highest predictive value among single markers. In patients who were treated and followed up, <fc>KL</fc>‐6 concentrations increased with the progression of <fc>ILD</fc> and decreased along with the improvement of <fc>ILD</fc>.</p></section><section xml:id="imj12754-sec-0005"><title type="main">Conclusion</title><p>Considering the ability of <fc>KL</fc>‐6 for predicting the onset of <fc>ILD</fc> and monitoring the treatment response of <fc>ILD</fc> in <fc>PM</fc>/<fc>DM</fc> patients, it may be of great significance for clinical practice, and the prognosis of patients may be substantially improved if serum <fc>KL</fc>‐6 was regularly monitored.</p></section></abstract></abstractGroup></contentMeta><noteGroup><note numbered="no" xml:id="imj12754-note-0001">Funding: This study was supported by The National Natural Science Foundation of China (Project number: 81072457) and Beijing Municipal Science and Technology Commission‐funded project (project number: D101100050010018).</note><note numbered="no" xml:id="imj12754-note-0002">Conflict of interest: None.</note></noteGroup></header> </component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Predictive value of serum markers</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study</title></titleInfo><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Chen</namePart><affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X.</namePart><namePart type="family">Lu</namePart><affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X.</namePart><namePart type="family">Shu</namePart><affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Q.</namePart><namePart type="family">Peng</namePart><affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X.</namePart><namePart type="family">Tian</namePart><affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Wang</namePart><affiliation>Department of Rheumatology, China‐Japan Friendship Hospital, Beijing, China</affiliation><affiliation>Guochun Wang, Department of Rheumatology, China‐Japan Friendship Hospital, Yinghua East Road, Chaoyang District, 100029 Beijing, China.Email:</affiliation><affiliation>E-mail: guochunwang@hotmail.com</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><dateIssued encoding="w3cdtf">2015-06</dateIssued><dateCreated encoding="w3cdtf">2015-04-13</dateCreated><dateCaptured encoding="w3cdtf">2014-10-20</dateCaptured><dateValid encoding="w3cdtf">2015-03-22</dateValid><copyrightDate encoding="w3cdtf">2015</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract>Background: Interstitial lung disease (ILD) is one of the most common and devastated complication of polymyositis/dermatomyositis (PM/DM). Several studies have focused on serum biomarkers for ILD in PM/DM patients; however, there have been no prospective studies. Aim: To explore and compare the predictive value of four serum markers for the development of ILD in patients with PM/DM. Methods: One hundred adult PM/DM patients were included in this prospective clinical study at baseline. Forty‐four PM/DM patients without ILD were followed up for 1 year. Fifty‐six PM/DM patients with ILD were treated and followed up for 2 months. Serum samples were analysed for the levels of Krebs von den Lungen‐6 (KL‐6), monocyte chemotactic protein‐1 (MCP‐1), surfactant protein‐A and D (SP‐A, SP‐D). Results: Serum KL‐6 (1542.8 ± 760.8 U/mL) (P < 0.001), MCP‐1 (1870 ± 1590 pg/mL) (P = 0.014), SP‐A (56 ± 28 ng/mL) (P < 0.001) and SP‐D (230 ± 196 ng/mL) (P < 0.001) were significantly elevated in PM/DM patients with ILD compared with those in the patients without ILD (KL‐6 429 ± 105.8 U/mL; MCP‐1 1349 ± 1303 pg/mL; SP‐A 34 ± 26 ng/mL; SP‐D 96 ± 63 ng/mL). In PM/DM patients without ILD who were followed up for 1 year, KL‐6 presented the highest predictive value among single markers. In patients who were treated and followed up, KL‐6 concentrations increased with the progression of ILD and decreased along with the improvement of ILD. Conclusion: Considering the ability of KL‐6 for predicting the onset of ILD and monitoring the treatment response of ILD in PM/DM patients, it may be of great significance for clinical practice, and the prognosis of patients may be substantially improved if serum KL‐6 was regularly monitored.</abstract><note type="funding">National Natural Science Foundation of China - No. 81072457; </note><note type="funding">Beijing Municipal Science and Technology Commission - No. D101100050010018; </note><subject><genre>keywords</genre><topic>myositis</topic><topic>lung disease</topic><topic>interstitial</topic><topic>predictive value</topic><topic>KL‐6</topic></subject><relatedItem type="host"><titleInfo><title>Internal Medicine Journal</title></titleInfo><titleInfo type="abbreviated"><title>Intern Med J</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Original Articles</topic><topic>Original Article</topic></subject><identifier type="ISSN">1444-0903</identifier><identifier type="eISSN">1445-5994</identifier><identifier type="DOI">10.1111/(ISSN)1445-5994</identifier><identifier type="PublisherID">IMJ</identifier><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>641</start><end>647</end><total>7</total></extent></part></relatedItem><relatedItem type="references" displayLabel="imj12754-cit-0001"><titleInfo><title>Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Kumánovics</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Minier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Radics</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Pálinkás</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Berki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Czirják</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kumánovics G, Minier T, Radics J, Pálinkás L, Berki T, Czirják L. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol 2008; 26: 414–420.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>414</start><end>420</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Rheumatol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>414</start><end>420</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="imj12754-cit-0002"><titleInfo><title>Sequential changes of KL‐6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Bandoh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Fujita</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Ohtsuki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Ueda</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Hojo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Tokuda</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bandoh S, Fujita J, Ohtsuki Y, Ueda Y, Hojo S, Tokuda M et al. Sequential changes of KL‐6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis. Ann Rheum Dis 2000; 59: 257–262.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><extent unit="pages"><start>257</start><end>262</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><extent unit="pages"><start>257</start><end>262</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="imj12754-cit-0003"><titleInfo><title>Serum KL‐6 in adult patients with polymyositis and dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Kubo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Ihn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Yamane</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Kikuchi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Yazawa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Soma</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kubo M, Ihn H, Yamane K, Kikuchi K, Yazawa N, Soma Y et al. Serum KL‐6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford) 2000; 39: 632–636.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>632</start><end>636</end></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology (Oxford)</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>632</start><end>636</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="imj12754-cit-0004"><titleInfo><title>A case of very late‐onset systemic lupus erythematosus and updated pooled analysis of late‐onset cases in the literature</title></titleInfo><name type="personal"><namePart type="given">F</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Zhang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chen F, Zhang L, Wang G, Lin B, Wang L. A case of very late‐onset systemic lupus erythematosus and updated pooled analysis of late‐onset cases in the literature. Rheumatol Int 2012; 32: 2993–2997.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>2993</start><end>2997</end></extent></part><relatedItem type="host"><titleInfo><title>Rheumatol Int</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>2993</start><end>2997</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="imj12754-cit-0005"><titleInfo><title>Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)</title></titleInfo><name type="corporate"><namePart>American Thoracic Society</namePart></name><genre>journal-article</genre><note type="citation/reference">American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646–664.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>161</number></detail><extent unit="pages"><start>646</start><end>664</end></extent></part><relatedItem type="host"><titleInfo><title>Am J Respir Crit Care Med</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>161</number></detail><extent unit="pages"><start>646</start><end>664</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="imj12754-cit-0006"><titleInfo><title>Polymyositis and dermatomyositis (first of the two parts)</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Bohan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JB</namePart><namePart type="family">Peter</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bohan A, Peter JB. Polymyositis and dermatomyositis (first of the two parts). N Engl J Med 1975; 292: 344–347.</note><part><date>1975</date><detail type="volume"><caption>vol.</caption><number>292</number></detail><extent unit="pages"><start>344</start><end>347</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>1975</date><detail type="volume"><caption>vol.</caption><number>292</number></detail><extent unit="pages"><start>344</start><end>347</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="imj12754-cit-0007"><titleInfo><title>Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis</title></titleInfo><name type="personal"><namePart type="given">PD</namePart><namePart type="family">Kiely</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Chua</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kiely PD, Chua F. Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis. Curr Rheumatol Rep 2013; 15: 359.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>359</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Rheumatol Rep</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>359</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="imj12754-cit-0008"><titleInfo><title>KL‐6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Fathi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Barbasso Helmers</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IE</namePart><namePart type="family">Lundberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fathi M, Barbasso Helmers S, Lundberg IE. KL‐6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med 2012; 271: 589–597.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>271</number></detail><extent unit="pages"><start>589</start><end>597</end></extent></part><relatedItem type="host"><titleInfo><title>J Intern Med</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>271</number></detail><extent unit="pages"><start>589</start><end>597</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="imj12754-cit-0009"><titleInfo><title>Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity</title></titleInfo><name type="personal"><namePart type="given">F</namePart><namePart type="family">Suzuki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Kubota</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Miyazaki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Ishikawa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Ebisawa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Hirohata</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Suzuki F, Kubota T, Miyazaki Y, Ishikawa K, Ebisawa M, Hirohata S et al. Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity. Arthritis Res Ther 2012; 14: R48.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>R48</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Res Ther</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>R48</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="imj12754-cit-0010"><titleInfo><title>Biomarkers in connective tissue disease‐associated interstitial lung disease</title></titleInfo><name type="personal"><namePart type="given">F</namePart><namePart type="family">Bonella</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">U</namePart><namePart type="family">Costabel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bonella F, Costabel U. Biomarkers in connective tissue disease‐associated interstitial lung disease. Semin Respir Crit Care Med 2014; 35: 181–200.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>181</start><end>200</end></extent></part><relatedItem type="host"><titleInfo><title>Semin Respir Crit Care Med</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>181</start><end>200</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="imj12754-cit-0011"><titleInfo><title>Surfactant protein A and surfactant protein D variation in pulmonary disease</title></titleInfo><name type="personal"><namePart type="given">GL</namePart><namePart type="family">Sorensen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Husby</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">U</namePart><namePart type="family">Holmskov</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sorensen GL, Husby S, Holmskov U. Surfactant protein A and surfactant protein D variation in pulmonary disease. Immunobiology 2007; 212: 381–416.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>212</number></detail><extent unit="pages"><start>381</start><end>416</end></extent></part><relatedItem type="host"><titleInfo><title>Immunobiology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>212</number></detail><extent unit="pages"><start>381</start><end>416</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="imj12754-cit-0012"><titleInfo><title>Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Takahashi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Shiratori</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Kanai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Chiba</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Kuroki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Abe</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Takahashi H, Shiratori M, Kanai A, Chiba H, Kuroki Y, Abe S. Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D. Respirology 2006; 11(Suppl): S51–54.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><detail type="issue"><caption>no.</caption><number>Suppl</number></detail><extent unit="pages"><start>S51</start><end>54</end></extent></part><relatedItem type="host"><titleInfo><title>Respirology</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><detail type="issue"><caption>no.</caption><number>Suppl</number></detail><extent unit="pages"><start>S51</start><end>54</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="imj12754-cit-0013"><titleInfo><title>Significant involvement of CCL2 (MCP‐1) in inflammatory disorders of the lung</title></titleInfo><name type="personal"><namePart type="given">CE</namePart><namePart type="family">Rose</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SS</namePart><namePart type="family">Sung</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SM</namePart><namePart type="family">Fu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rose CE, Sung SS, Fu SM. Significant involvement of CCL2 (MCP‐1) in inflammatory disorders of the lung. Microcirculation 2003; 10: 273–288.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>273</start><end>288</end></extent></part><relatedItem type="host"><titleInfo><title>Microcirculation</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>273</start><end>288</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="imj12754-cit-0014"><titleInfo><title>Clinical significance of MCP‐1 levels in BALF and serum in patients with interstitial lung diseases</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Suga</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Iyonaga</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Ichiyasu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Saita</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Yamasaki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Ando</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Suga M, Iyonaga K, Ichiyasu H, Saita N, Yamasaki H, Ando M. Clinical significance of MCP‐1 levels in BALF and serum in patients with interstitial lung diseases. Eur Respir J 1999; 14: 376–382.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>376</start><end>382</end></extent></part><relatedItem type="host"><titleInfo><title>Eur Respir J</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>376</start><end>382</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="imj12754-cit-0015"><titleInfo><title>Utility of KL‐6/MUC1 in the clinical management of interstitial lung diseases</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Ishikawa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Hattori</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Yokoyama</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Kohno</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ishikawa N, Hattori N, Yokoyama A, Kohno N. Utility of KL‐6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig 2012; 50: 3–13.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>3</start><end>13</end></extent></part><relatedItem type="host"><titleInfo><title>Respir Investig</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>3</start><end>13</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="imj12754-cit-0016"><titleInfo><title>Comparative study of KL‐6, surfactant protein‐A, surfactant protein‐D, and monocyte chemoattractant protein‐1 as serum markers for interstitial lung diseases</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Ohnishi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Yokoyama</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Kondo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Hamada</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Abe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Nishimura</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K et al. Comparative study of KL‐6, surfactant protein‐A, surfactant protein‐D, and monocyte chemoattractant protein‐1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002; 165: 378–381.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>165</number></detail><extent unit="pages"><start>378</start><end>381</end></extent></part><relatedItem type="host"><titleInfo><title>Am J Respir Crit Care Med</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>165</number></detail><extent unit="pages"><start>378</start><end>381</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="imj12754-cit-0017"><titleInfo><title>Clinical significance of serum surfactant protein D (SP‐D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Ihn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Asano</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Kubo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Yamane</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Jinnin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Yazawa</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ihn H, Asano Y, Kubo M, Yamane K, Jinnin M, Yazawa N et al. Clinical significance of serum surfactant protein D (SP‐D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease. Rheumatology (Oxford) 2002; 41: 1268–1272.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1268</start><end>1272</end></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology (Oxford)</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1268</start><end>1272</end></extent></part></relatedItem></relatedItem><identifier type="istex">249174A4FE3F03904034F8D234EFBBD08C7B3A72</identifier><identifier type="ark">ark:/67375/WNG-ZKV2GC5X-V</identifier><identifier type="DOI">10.1111/imj.12754</identifier><identifier type="ArticleID">IMJ12754</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2015 Royal Australasian College of Physicians© 2015 Royal Australasian College of Physicians</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-15</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-ZKV2GC5X-V/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001596 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001596 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:249174A4FE3F03904034F8D234EFBBD08C7B3A72
|texte= Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study
}}
| This area was generated with Dilib version V0.6.33. |  |